{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:33:36Z","timestamp":1791855216631,"version":"4.3.4"},"reference-count":10,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,7,1]]},"DOI":"10.1182\/blood-2009-11-252155","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T16:43:57Z","timestamp":1278002637000},"page":"5428-5429","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Uncommon BCR-ABL kinase domain mutations in kinase inhibitor\u2013resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects"],"prefix":"10.1182","volume":"115","author":[{"given":"Dan","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su S.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Rios","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111814150796500_B1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2019111814150796500_B2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.","volume":"11","author":"Jones","year":"2009","journal-title":"J Mol Diagn"},{"issue":"12","key":"2019111814150796500_B3","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111814150796500_B4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"2019111814150796500_B5","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111814150796500_B6","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111814150796500_B7","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111814150796500_B8","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"11","key":"2019111814150796500_B9","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111814150796500_B10","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/26\/5428\/1297090\/zh802610005428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/26\/5428\/1297090\/zh802610005428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:15:16Z","timestamp":1574104516000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/115\/26\/5428\/130852\/Uncommon-BCRABL-kinase-domain-mutations-in-kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,1]]},"references-count":10,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2010,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-11-252155","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,1]]}}}